CME: Cold agglutinin disease (CAD): Updates from the American Society of Hematology (ASH) 2019 annual meeting
Cost: FreeView Offer chevron_right
Cold agglutinin disease (CAD) is a subtype of autoimmune hemolytic anemia (AIHA) and characterized by cold agglutinin (CA) autoantibodies that cause the erythrocytic hemolysis. Also known as primary or idiopathic CAD, it is distinguished further from cold agglutinin syndrome (CAS), which is a complication of known conditions such as malignancy, infection, or autoimmune disease. Little is known about the epidemiology of CAD; one small study estimated incidence of 1 per 1 million people and prevalence of 1 per 16 million people with females twice as likely males to develop the disease and a median age of onset of 67 years.
By the end of the session the participant will be able to:
- Describe the pathogenesis and symptomology of AIHA generally and CAD specifically
- Describe how diagnosis of CAD is distinguished from other subtypes of AIHA and challenges to successful identification of patients
- Describe present and emerging treatment options for CAD and monitoring parameters for effectiveness of treatment
- Develop a safe and clinically effective treatment plan including non-pharmacologic and pharmacologic therapy for patients with CAD
The following healthcare professionals (HCPs): hematologists, oncologists, immunologists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CAD.